Cardiol Therapeutics Statistics
Total Valuation
CRDL has a market cap or net worth of $93.53 million. The enterprise value is $77.00 million.
Important Dates
The next estimated earnings date is Tuesday, May 27, 2025, after market close.
| Earnings Date | May 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CRDL has 82.61 million shares outstanding. The number of shares has increased by 11.02% in one year.
| Current Share Class | 82.61M |
| Shares Outstanding | 82.61M |
| Shares Change (YoY) | +11.02% |
| Shares Change (QoQ) | +15.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 78.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.64 |
| P/TBV Ratio | 7.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.26, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.26 |
| Quick Ratio | 3.05 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -190.11% and return on invested capital (ROIC) is -132.69%.
| Return on Equity (ROE) | -190.11% |
| Return on Assets (ROA) | -89.03% |
| Return on Invested Capital (ROIC) | -132.69% |
| Return on Capital Employed (ROCE) | -227.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.38M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.16% in the last 52 weeks. The beta is 0.66, so CRDL's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -52.16% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.52 |
| Relative Strength Index (RSI) | 52.43 |
| Average Volume (20 Days) | 142,254 |
Short Selling Information
The latest short interest is 2.02 million, so 2.44% of the outstanding shares have been sold short.
| Short Interest | 2.02M |
| Short Previous Month | 2.04M |
| Short % of Shares Out | 2.44% |
| Short % of Float | 2.56% |
| Short Ratio (days to cover) | 11.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -28.04M |
| Pretax Income | -21.99M |
| Net Income | -24.90M |
| EBITDA | -27.95M |
| EBIT | -28.04M |
| Earnings Per Share (EPS) | -$0.33 |
Full Income StatementBalance Sheet
The company has $16.21 million in cash and $104,818 in debt, giving a net cash position of $16.10 million or $0.19 per share.
| Cash & Cash Equivalents | 16.21M |
| Total Debt | 104,818 |
| Net Cash | 16.10M |
| Net Cash Per Share | $0.19 |
| Equity (Book Value) | 12.24M |
| Book Value Per Share | 0.15 |
| Working Capital | 12.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.60 million and capital expenditures -$20,711, giving a free cash flow of -$17.96 million.
| Operating Cash Flow | -17.60M |
| Capital Expenditures | -20,711 |
| Free Cash Flow | -17.96M |
| FCF Per Share | -$0.22 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |